|
|
| | Obexelimab Basic information |
| Product Name: | Obexelimab | | Synonyms: | Obexelimab;Research Grade Obexelimab;Obexelimab (anti-CD19) | | CAS: | 1690307-05-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Obexelimab Structure]() |
| | Obexelimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Obexelimab Usage And Synthesis |
| Uses | Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus[1][2][3]. | | in vivo | Obexelimab (10 mg/kg; twice a week; i.p.) can inhibit the autoimmune response of immune deficient mice implanted with peripheral blood mononuclear cells (PBMCs) from rheumatoid arthritis (RA) patients[2]. | Animal Model: | Female C.B-17 SCID mice transplanted with PBMCs[2]. | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.); twice a week | | Result: | Resulted in inhibition of various immune responses in mice, including IgG, IgM, RF, ACPA, and anti-tetanus antibodies. |
| | References | [1] Boyles JS, et al. A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases. JCI Insight. 2023 Jul 10;8(13):e166137. DOI:10.1172/jci.insight.166137
[2] Chu SY, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol. 2014 May;66(5):1153-64. DOI:10.1002/art.38334
[3] Horton HM, et al. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011 Apr 1;186(7):4223-33. DOI:10.4049/jimmunol.1003412 |
| | Obexelimab Preparation Products And Raw materials |
|